ESMO 2025 | Advancements in developing inhibitors for non-G12C KRAS mutations

Matteo Simonelli • 20 Oct 2025

ESMO 2025

General

Matteo Simonelli, MD, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy, discusses the advancements in developing inhibitors for non-G12C KRAS mutations, highlighting the improved safety profile of next-generation KRAS G12C inhibitors. Dr Simonelli notes that these covalent inhibitors have a well-tolerated safety profile while maintaining their activity as very active agents, showing significant improvement over the first generation of covalent G12C-specific inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think that, you know, that this next generation KRAS G12C inhibitors, covalent inhibitors, have a very well-tolerated safety profile. And this is the main characteristic. They are still active, very active agents, but a safety profile extremely better than the first generation of covalent G12C-specific inhibitors.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video...

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.